Informace o publikaci

Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients

Autoři

WEINBERGEROVÁ Barbora MAYER Jiří KABUT Tomáš HRABOVSKÝ Štěpán PROCHÁZKOVÁ Jiřina KRÁL Zdeněk HEROUT Vladimír PACASOVÁ Rita ZDRAŽILOVÁ DUBSKÁ Lenka HUSA Petr BEDNAR Petr RUZEK Daniel LENGEROVÁ Martina

Rok publikování 2021
Druh Článek v odborném periodiku
Časopis / Zdroj Hematological Oncology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://onlinelibrary.wiley.com/doi/10.1002/hon.2908
Doi http://dx.doi.org/10.1002/hon.2908
Klíčová slova COVID-19; remdesivir; hematological patients
Popis Immunocompromised patients with hematological malignancies are at high risk for a severe course of COVID-19 (Coronavirus Disease 2019) with a deadly outcome.1, 2 With remdesivir use, several randomized trials have recorded abbreviated recovery periods, lower mortality, and positive consequences of early treatment initiation.3, 4 Based on randomized trial results, the FDA has approved remdesivir for the treatment of COVID-19. Regarding convalescent plasma (CP), evidence from recently published large trials implies that early administration of high-titer CP is most efficacious.5 However, no published studies assessing the effect of remdesivir or CP in COVID-19 have included a substantial proportion of hematooncology patients, and available data are limited to case reports.6, 7 In view of this dearth of data, we decided to analyze the efficacy of early combination therapy of remdesivir and high-titer CP among hematological patients. This treatment strategy was implemented after observing several grim COVID-19 outcomes among these patients.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info